Moderna Shares Plunge After Leak of Cancer Vaccine Data
Moderna shares plunged as much as 25% after partial clinical trial data leaked for its personalized cancer vaccine developed with Merck, despite the full results showing promising outcomes for melanoma patients. Analysts attribute the selloff largely to inflated investor expectations rather than disappointing clinical results. CNBC reports: The personalized vaccine, kno … ⌘ Read more